0001567892-21-000008.txt : 20210310 0001567892-21-000008.hdr.sgml : 20210310 20210310064509 ACCESSION NUMBER: 0001567892-21-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210310 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210310 DATE AS OF CHANGE: 20210310 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Mallinckrodt plc CENTRAL INDEX KEY: 0001567892 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981088325 FISCAL YEAR END: 1225 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35803 FILM NUMBER: 21728208 BUSINESS ADDRESS: STREET 1: COLLEGE BUSINESS & TECHNOLOGY PARK STREET 2: CRUISERATH, BLANCHARDSTOWN CITY: DUBLIN 15 STATE: L2 ZIP: D15 BUSINESS PHONE: 353 1 6960000 MAIL ADDRESS: STREET 1: COLLEGE BUSINESS & TECHNOLOGY PARK STREET 2: CRUISERATH, BLANCHARDSTOWN CITY: DUBLIN 15 STATE: L2 ZIP: D15 8-K 1 mnk-20210310.htm 8-K mnk-20210310
0001567892false00015678922021-03-102021-03-10


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 10, 2021
 
Mallinckrodt plc
(Exact name of registrant as specified in its charter)
Ireland001-3580398-1088325
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
College Business & Technology Park, Cruiserath,
Blanchardstown, Dublin 15, Ireland
(Address of principal executive offices) (Zip Code)
 
Registrant's telephone number, including area code:  +353 1 696 0000

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: 
(Title of each class)
Ordinary shares, par value $0.20 per share
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



Item 2.02    Results of Operations and Financial Condition.
On March 10, 2021, Mallinckrodt plc (the "Company" or "Mallinckrodt") provided its financial results for the quarter and year ended December 25, 2020 in the attached Exhibit 99.1.
The information in this Current Report on Form 8-K, including Exhibit 99.1, should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended December 25, 2020.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as otherwise expressly set forth by specific reference in such a filing.
NON-GAAP FINANCIAL MEASURES
Exhibit 99.1 contains financial measures, including adjusted EBITDA and net sales growth on a constant-currency basis, which are considered "non-GAAP" financial measures under applicable U.S. Securities and Exchange Commission rules and regulations.
Adjusted EBITDA represents amounts prepared in accordance with accounting principles generally accepted in the U.S. (GAAP) and adjusts for certain items that management believes are not reflective of the operational performance of the business. Consolidated adjusted EBITDA represents net income (loss), adjusted for interest expense, net, taxes, depreciation and amortization and certain items that management believes are not reflective of the operational performance of the business and additional adjustments. These adjustments include, but are not limited to, restructuring charges, net; non-restructuring impairment charges; inventory step-up expense; discontinued operations; changes in fair value of contingent consideration obligations; significant legal and environmental charges; divestitures; separation costs; gain on debt extinguishment, net; unrealized gain on equity investment; research & development upfront payments; reorganization items, net; share-based compensation and other items identified by the Company.
Segment net sales growth on a constant-currency basis measures the change in segment net sales between current- and prior-year periods using a constant currency, the exchange rate in effect during the applicable prior-year period.
The Company has provided these adjusted financial measures because they are used by management, along with financial measures in accordance with GAAP, to evaluate the company's operating performance. In addition, the Company believes that they will be used by certain investors to measure Mallinckrodt's operating results. Management believes that presenting these adjusted measures provides useful information about the Company's performance across reporting periods on a consistent basis by excluding items that the Company does not believe are indicative of its core operating performance. Reconciliations of these financial measures to the most directly comparable GAAP financial measures are included in Exhibit 99.1.
These adjusted measures should be considered supplemental to and not a substitute for financial information prepared in accordance with GAAP.

Item 9.01    Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Exhibit
99.1
104Cover Page Interactive Data File (embedded within the inline XBRL document).



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MALLINCKRODT PLC
(registrant)
Date:March 10, 2021By: /s/ Bryan M. Reasons
Bryan M. Reasons
Executive Vice President and Chief Financial Officer
(principal financial officer)



 EX-99.1 2 mnk991q42020er.htm EX-99.1 Document

Exhibit 99.1

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)
Three Months Ended
December 25,
2020		Percent of
Net sales		December 27,
2019		Percent of
Net sales
Net sales
$682.8 100.0 %$804.9 100.0 %
Cost of sales372.3 54.5 431.8 53.6 
Gross profit310.5 45.5 373.1 46.4 
Selling, general and administrative expenses200.9 29.4 169.2 21.0 
Research and development expenses65.0 9.5 81.4 10.1 
Restructuring charges, net21.7 3.2 (12.9)(1.6)
Non-restructuring impairment charges— — 274.5 34.1 
(Gains) losses on divestiture(6.5)(1.0)33.5 4.2 
Opioid-related litigation settlement (gain) loss(9.3)(1.4)1,643.4 204.2 
Operating income (loss)38.7 5.7 (1,816.0)(225.6)
Interest expense(60.2)(8.8)(77.2)(9.6)
Interest income0.5 0.1 2.9 0.4 
Gain on debt extinguishment, net— — 377.4 46.9 
Other income, net6.3 0.9 24.2 3.0 
Reorganization items, net(61.4)(9.0)— — 
Loss from continuing operations before income taxes(76.1)(11.1)(1,488.7)(185.0)
Income tax expense (benefit)78.1 11.4 (327.7)(40.7)
Loss from continuing operations(154.2)(22.6)(1,161.0)(144.2)
Income from discontinued operations, net of income taxes1.3 0.2 3.9 0.5 
Net loss$(152.9)(22.4)%$(1,157.1)(143.8)%
Basic loss per share:
Loss from continuing operations$(1.82)$(13.80)
Income from discontinued operations0.02 0.05 
Net loss$(1.81)$(13.76)
Diluted loss per share:
Loss from continuing operations$(1.82)$(13.80)
Income from discontinued operations0.02 0.05 
Net loss$(1.81)$(13.76)
Weighted-average number of shares outstanding
Basic weighted-average shares outstanding84.684.1
Diluted weighted-average shares outstanding84.684.1







1

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONSOLIDATED ADJUSTED EBITDA
(unaudited, in millions)
Three Months Ended
December 25, 2020December 27, 2019
Gross ProfitSG&AR&DAdjusted EBITDAGross ProfitSG&AR&DAdjusted EBITDA
Net loss$310.5 $200.9 $65.0 $(152.9)$373.1 $169.2 $81.4 $(1,157.1)
Adjustments:
Interest expense, net— — — 59.7 — — — 74.3 
Income taxes— — — 78.1 — — — (327.7)
Depreciation(1)
17.7 (18.8)(1.8)38.3 16.1 (5.8)(2.1)24.0 
Amortization170.6 (0.8)— 171.4 202.8 (0.8)— 203.6 
Restructuring charges, net— — — 21.7 — — — (12.9)
Non-restructuring impairment charge— — — — — — — 274.5 
Income from discontinued operations— — — (1.3)— — — (3.9)
Change in contingent consideration fair value— (7.5)— 7.5 — 36.7 — (36.7)
Significant legal and environmental charges (2)
0.9 (2.6)— (5.8)— — — 1,643.4 
(Gains) losses on divestiture— — — (6.5)— — — 33.5 
Separation costs— (18.4)— 18.4 — (13.5)— 13.5 
Gains on debt extinguishment, net— — — — — — — (377.4)
Unrealized gain on equity investment— — — (1.6)— — — (13.7)
Reorganization items, net— — — 61.4 — — — — 
Share-based compensation 0.4 (6.0)(1.3)7.7 0.2 (2.6)(0.4)3.2 
As adjusted:$500.1 $146.8 $61.9 $296.1 $592.2 $183.2 $78.9 $340.6 
(1)Includes $12.3 million of accelerated depreciation in selling general and administrative ("SG&A") related to restructuring charges incurred during the three months ended December 25, 2020.
(2)Includes a $9.3 million decrease in the fair value of the opioid settlement warrants, partially offset by $2.6 million in opioid defense costs and a $0.9 million change to the retrospective Medicaid lawsuit liability. Opioid defense costs are considered to be non-recurring as a result of the opioid-related litigation settlement announced during the three months ended March 27, 2020; therefore, such costs are included as an adjustment to net income on a go-forward basis.



2

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT OPERATING INCOME (1)
(unaudited, in millions)
Three Months Ended
December 25,
2020		December 27,
2019
Specialty Brands$250.7 $315.9 
Specialty Generics50.9 43.1 
Segment operating income301.6 359.0 
Unallocated amounts:
Corporate and unallocated expenses (2)
(13.8)(25.7)
Depreciation and amortization(209.7)(227.6)
Share-based compensation(7.7)(3.2)
Restructuring charges, net(21.7)12.9 
Non-restructuring impairment charges— (274.5)
Separation costs(18.4)(13.5)
Opioid-related litigation settlement gain (loss)9.3 (1,643.4)
Medicaid lawsuit(0.9)— 
Operating income (loss)$38.7 $(1,816.0)
(1)During the three months ended September 25, 2020, the Company began excluding depreciation and share-based compensation from its evaluation of the operating results of its segments. As a result, prior period segment operating income has been recast to reflect this change on a comparable basis.
(2)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.
3

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
Three Months Ended
December 25,
2020		December 27,
2019		Percent
change		Currency impactConstant-currency growth
Specialty Brands$506.6 $611.4 (17.1)%0.1 %(17.2)%
Specialty Generics177.1 193.5 (8.5)— (8.5)
Segment net sales683.7 804.9 (15.1)0.1 (15.2)
Medicaid lawsuit(0.9)— ***
Net sales$682.8 $804.9 (15.2)%0.1 %(15.3)%
*Not meaningful
MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SELECT PRODUCT LINE NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
Three Months Ended
December 25,
2020		December 27,
2019		Percent
change		Currency impactConstant-currency growth
Specialty Brands
Acthar Gel$191.3 $232.6 (17.8)%— %(17.8)%
INOmax135.6 143.8 (5.7)0.1 (5.8)
Ofirmev60.5 111.8 (45.9)— (45.9)
Therakos64.5 63.3 1.9 1.2 0.7 
Amitiza50.6 50.9 (0.6)— (0.6)
Other4.1 9.0 (54.4)— (54.4)
Specialty Brands Total506.6 611.4 (17.1)0.1 (17.2)
Specialty Generics
Hydrocodone (API) and hydrocodone-containing tablets26.1 25.1 4.0 — 4.0 
Oxycodone (API) and oxycodone-containing tablets20.4 21.6 (5.6)— (5.6)
Acetaminophen (API)58.5 46.8 25.0 — 25.0 
Other controlled substances66.1 86.8 (23.8)— (23.8)
Other6.0 13.2 (54.5)— (54.5)
Specialty Generics Total177.1 193.5 (8.5)— (8.5)
Segment net sales683.7 804.9 (15.1)0.1 (15.2)
Medicaid lawsuit(0.9)— ***
Net sales$682.8 $804.9 (15.2)%0.1 %(15.3)%
*Not meaningful



4

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in millions, except per share data)
Fiscal Year
December 25,
2020		Percent of
Net sales		December 27,
2019		Percent of
Net sales
Net sales (includes refined estimate of the retrospective one-time charge of $536.0 related to the Medicaid lawsuit for the fiscal year ended December 25, 2020)
$2,213.4 100.0 %$3,162.5 100.0 %
Cost of sales1,544.0 69.8 1,741.1 55.1 
Gross profit669.4 30.2 1,421.4 44.9 
Selling, general and administrative expenses884.1 39.9 831.0 26.3 
Research and development expenses290.8 13.1 349.4 11.0 
Restructuring charges, net37.5 1.7 (1.7)(0.1)
Non-restructuring impairment charges63.5 2.9 388.0 12.3 
(Gains) losses on divestiture(16.6)(0.7)33.5 1.1 
Opioid-related litigation settlement (gain) loss(43.4)(2.0)1,643.4 52.0 
Medicaid lawsuit105.1 4.7 — — 
Operating loss(651.6)(29.4)(1,822.2)(57.6)
Interest expense(261.1)(11.8)(309.0)(9.8)
Interest income5.9 0.3 9.5 0.3 
Gains on debt extinguishment, net— — 466.6 14.8 
Other income, net7.4 0.3 63.6 2.0 
Reorganization items, net(61.4)(2.8)— — 
Loss from continuing operations before income taxes
(960.8)(43.4)(1,591.5)(50.3)
Income tax expense (benefit)8.9 0.4 (584.3)(18.5)
Loss from continuing operations(969.7)(43.8)(1,007.2)(31.8)
Income from discontinued operations, net of income taxes
25.1 1.1 10.7 0.3 
Net loss$(944.6)(42.7)%$(996.5)(31.5)%
Basic loss per share:
Loss from continuing operations$(11.48)$(12.00)
Income from discontinued operations0.30 0.13 
Net loss$(11.18)$(11.88)
Diluted loss per share:
Loss from continuing operations$(11.48)$(12.00)
Income from discontinued operations0.30 0.13 
Net loss$(11.18)$(11.88)
Weighted-average number of shares outstanding:
Basic84.583.9
Diluted84.583.9

5

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONSOLIDATED ADJUSTED EBITDA
(unaudited, in millions)
Fiscal Year
December 25, 2020December 27, 2019
Gross ProfitSG&AR&DAdjusted EBITDAGross ProfitSG&AR&DAdjusted EBITDA
Net loss$669.4 $884.1 $290.8 $(944.6)$1,421.4 $831.0 $349.4 $(996.5)
Adjustments:
Interest expense, net— — — 255.2 — — — 299.5 
Income taxes— — — 8.9 — — — (584.3)
Depreciation(1)
71.9 (35.1)(7.0)114.0 67.7 (22.2)(7.8)97.7 
Amortization767.8 (3.4)— 771.2 847.9 (5.5)— 853.4 
Restructuring charges, net— — — 37.5 — — — (1.7)
Non-restructuring impairment charge— — — 63.5 — — — 388.0 
Inventory step-up expense— — — — 10.0 — — 10.0 
Income from discontinued operations— — — (25.1)— — — (10.7)
Change in contingent consideration fair value— (9.9)— 9.9 — 60.2 — (60.2)
Significant legal and environmental charges (2)
536.0 (55.7)— 653.4 — (28.2)— 1,671.6 
(Gains) losses on divestiture— — — (16.6)— — — 33.5 
Separation costs— (93.4)— 93.4 — (63.9)— 63.9 
Gain on debt extinguishment, net— — — — — — — (466.6)
Unrealized gain on equity investment— — — (3.8)— — — (20.2)
R&D upfront payment— — (5.0)5.0 — — (20.0)20.0 
Reorganization items, net— — — 61.4 — — — — 
Share-based compensation1.3 (19.9)(4.1)25.3 1.9 (26.7)(5.2)33.8 
As adjusted:$2,046.4 $666.7 $274.7 $1,108.6 $2,348.9 $744.7 $316.4 $1,331.2 
1300000-19900000-4100000
(1)Includes $12.3 million of accelerated depreciation in SG&A related to restructuring charges incurred during fiscal 2020.
(2)Includes a retrospective one-time charge of $641.1 million (the "Acthar Gel Medicaid Retrospective Rebate"), of which $536.0 million and $105.1 million have been reflected as a component of net sales and operating expenses, respectively, in the condensed consolidated statement of operations for the fiscal year ended December 25, 2020. The $105.1 million reflected as a component of operating expenses represents a pre-acquisition contingency related to the portion of the Acthar Gel Medicaid Retrospective Rebate that arose from sales of Acthar Gel prior to the Company’s acquisition of Questcor Pharmaceuticals, Inc. in August 2014. Also includes $55.7 million in opioid defense costs which are considered to be non-recurring as a result of the opioid-related litigation settlement announced during the three months ended March 27, 2020; therefore, such costs are included as an adjustment to net income on a go-forward basis. These costs were partially offset by a $43.4 million decrease in the fair value of the opioid settlement warrants.

6

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT OPERATING INCOME (1)
(unaudited, in millions)
Fiscal Year
December 25,
2020		December 27,
2019
Specialty Brands$1,015.7 $1,210.1 
Specialty Generics206.4 168.5 
Segment operating income1,222.1 1,378.6 
Unallocated amounts:
Corporate and unallocated expenses (2)
(166.1)(102.3)
Depreciation and amortization(885.2)(951.1)
Share-based compensation(25.3)(33.8)
Restructuring charges, net(37.5)1.7 
Non-restructuring impairment charges(63.5)(388.0)
Separation costs(93.4)(63.9)
R&D upfront payment(5.0)(20.0)
Opioid-related litigation settlement gain (loss)43.4 (1,643.4)
Medicaid lawsuit(641.1)— 
Operating loss$(651.6)$(1,822.2)
(1)During the three months ended September 25, 2020, the Company began excluding depreciation and share-based compensation from its evaluation of the operating results of its segments. As a result, prior period segment operating income has been recast to reflect this change on a comparable basis.
(2)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

7

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SEGMENT NET SALES AND CONSTANT-CURRENCY GROWTH
(unaudited, in millions)
Fiscal Year
December 25,
2020		December 27,
2019		Percent
change		Currency impactConstant-currency growth
Specialty Brands$2,059.6 $2,423.8 (15.0)%— %(15.0)%
Specialty Generics689.8 738.7 (6.6)— (6.6)
Segment net sales2,749.4 3,162.5 (13.1)— (13.1)
Medicaid lawsuit(536.0)— ***
Net sales$2,213.4 $3,162.5 (30.0)%— %(30.0)%
*Not meaningful
MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
SELECT PRODUCT LINE NET SALES
(unaudited, in millions)
Fiscal Year
December 25,
2020		December 27,
2019		Percent
change		Currency impactConstant-currency growth
Specialty Brands
Acthar$767.9 $952.7 (19.4)%— %(19.4)%
Inomax574.1 571.4 0.5 — 0.5 
Ofirmev276.5 384.0 (28.0)— (28.0)
Therakos238.6 246.9 (3.4)0.3 (3.7)
Amitiza188.8 208.5 (9.4)— (9.4)
Other13.7 60.3 (77.3)— (77.3)
Specialty Brands Total2,059.6 2,423.8 (15.0)— (15.0)
Specialty Generics
Hydrocodone (API) and hydrocodone-containing tablets98.0 76.3 28.4 — 28.4 
Oxycodone (API) and oxycodone-containing tablets68.4 74.9 (8.7)— (8.7)
Acetaminophen (API)213.0 189.9 12.2 — 12.2 
Other controlled substances289.9 352.5 (17.8)— (17.8)
Other20.5 45.1 (54.5)— (54.5)
Specialty Generics Total689.8 738.7 (6.6)— (6.6)
Segment net sales2,749.4 3,162.5 (13.1)— (13.1)
Medicaid lawsuit536.0 — ***
Net sales$2,213.4 $3,162.5 (30.0)%— %(30.0)%
*Not meaningful
8

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in millions)
December 25,
2020		December 27,
2019
Assets
Current Assets:
Cash and cash equivalents$1,070.6 $790.9 
Accounts receivable, net538.8 577.5 
Inventories344.9 312.1 
Prepaid expenses and other current assets350.0 150.2 
Total current assets2,304.3 1,830.7 
Property, plant and equipment, net833.1 896.5 
Intangible assets, net6,184.5 7,018.0 
Other assets393.5 593.7 
Total Assets$9,715.4 $10,338.9 
Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt$3,587.9 $633.6 
Accounts payable93.3 139.8 
Accrued payroll and payroll-related costs79.4 105.2 
Accrued interest26.9 62.9 
Accrued and other current liabilities331.2 485.4 
Total current liabilities4,118.7 1,426.9 
Long-term debt— 4,741.2 
Opioid-related litigation settlement liability— 1,643.4 
Pension and postretirement benefits34.6 62.4 
Environmental liabilities59.8 60.0 
Deferred income taxes80.6 11.0 
Other income tax liabilities100.1 227.1 
Other liabilities109.8 226.2 
Liabilities subject to compromise4,192.6 — 
Total Liabilities8,696.2 8,398.2 
Shareholders' Equity:
Preferred shares— — 
Ordinary shares
18.8 18.7 
Ordinary shares held in treasury at cost(1,616.1)(1,615.7)
Additional paid-in capital5,587.6 5,562.5 
Retained deficit(2,961.5)(2,016.9)
Accumulated other comprehensive loss(9.6)(7.9)
Total Shareholders' Equity1,019.2 1,940.7 
Total Liabilities and Shareholders' Equity$9,715.4 $10,338.9 


9

MALLINCKRODT PLC
(DEBTOR-IN-POSSESSION)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited, in millions)
Fiscal Year
December 25,
2020		December 27,
2019
Cash Flows From Operating Activities:
Net loss$(944.6)$(996.5)
Adjustments to reconcile net cash from operating activities:
Depreciation and amortization885.2 951.1 
Share-based compensation25.3 33.8 
Deferred income taxes385.3 (604.3)
Non-cash impairment charges63.5 388.0 
Inventory provisions18.5 18.0 
(Gains) losses on divestiture(16.6)33.5 
Gain on repurchase of debt— (466.6)
Other non-cash items(40.2)(65.7)
Reorganization items, net10.2 — 
Changes in assets and liabilities:
Accounts receivable, net37.9 31.6 
Inventories(51.1)(23.1)
Accounts payable15.7 6.7 
Income taxes(433.8)(2.1)
Opioid-related litigation settlement liability— 1,600.0 
Medicaid lawsuit638.9 — 
Other(95.3)(161.5)
Net cash from operating activities498.9 742.9 
Cash Flows From Investing Activities:
Capital expenditures(47.7)(133.0)
Proceeds from divestiture, net of cash(0.7)95.1 
Other37.2 29.6 
Net cash from investing activities(11.2)(8.3)
Cash Flows From Financing Activities:
Issuance of external debt— 695.0 
Repayment of external debt(139.5)(945.1)
Debt financing costs(9.4)(10.1)
Proceeds from exercise of share options— 0.6 
Repurchase of shares(0.4)(2.6)
Other(36.3)(17.9)
Net cash from financing activities(185.6)(280.1)
Effect of currency rate changes on cash2.3 0.6 
Net change in cash, cash equivalents and restricted cash304.4 455.1 
Cash, cash equivalents and restricted cash at beginning of period822.6 367.5 
Cash, cash equivalents and restricted cash at end of period$1,127.0 $822.6 
Cash and cash equivalents at end of period$1,070.6 $790.9 
Restricted cash included in prepaid expenses and other assets at end of period20.2 — 
Restricted cash included in other long-term assets at end of period36.2 31.7 
Cash, cash equivalents and restricted cash at end of period$1,127.0 $822.6 
10
 EX-101.SCH 3 mnk-20210310.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 mnk-20210310_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 mnk-20210310_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 mnk-20210310_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Country Region Country Region Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Amendment Flag Amendment Flag City Area Code City Area Code Written Communications Written Communications Entity Address, Address Line Three Entity Address, Address Line Three Title of 12(b) Security Title of 12(g) Security Document and Entity Information [Abstract] Document and Entity Information [Abstract] Document and Entity Information [Abstract] Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Country Entity Address, Country Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key EX-101.PRE 7 mnk-20210310_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 mnk-20210310_htm.xml IDEA: XBRL DOCUMENT 0001567892 2021-03-10 2021-03-10 0001567892 false 8-K 2021-03-10 Mallinckrodt plc L2 001-35803 98-1088325 College Business & Technology Park Cruiserath Blanchardstown Dublin 15 IE 353 1 696 0000 false false false false Ordinary shares, par value $0.20 per share false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information Document
Mar. 10, 2021
Document and Entity Information [Abstract]  
Entity Central Index Key 0001567892
Title of 12(b) Security Ordinary shares, par value $0.20 per share
Written Communications false
Entity Incorporation, State or Country Code L2
Document Type 8-K
Document Period End Date Mar. 10, 2021
Entity Registrant Name Mallinckrodt plc
Entity File Number 001-35803
Entity Tax Identification Number 98-1088325
Entity Address, Address Line One College Business & Technology Park
Entity Address, City or Town Dublin
Entity Address, Postal Zip Code 15
Entity Address, Country IE
City Area Code 1
Local Phone Number 696 0000
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Address, Address Line Two Cruiserath
Entity Address, Address Line Three Blanchardstown
Country Region 353
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 97 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Document Sheet http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports mnk-20210310.htm mnk-20210310.xsd mnk-20210310_cal.xml mnk-20210310_def.xml mnk-20210310_lab.xml mnk-20210310_pre.xml mnk991q42020er.htm http://xbrl.sec.gov/dei/2020-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mnk-20210310.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "mnk-20210310_cal.xml" ] }, "definitionLink": { "local": [ "mnk-20210310_def.xml" ] }, "inline": { "local": [ "mnk-20210310.htm" ] }, "labelLink": { "local": [ "mnk-20210310_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mnk-20210310_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mnk-20210310.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mnk", "nsuri": "http://www.mallinckrodt.com/20210310", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mnk-20210310.htm", "contextRef": "i2ebdc48042284756830585e0d2e50afe_D20210310-20210310", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12gTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information Document", "role": "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument", "shortName": "Document and Entity Information Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mnk-20210310.htm", "contextRef": "i2ebdc48042284756830585e0d2e50afe_D20210310-20210310", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12gTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.mallinckrodt.com/role/DocumentandEntityInformationDocument" ], "xbrltype": "booleanItemType" }, "mnk_DocumentandEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]", "terseLabel": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentandEntityInformationAbstract", "nsuri": "http://www.mallinckrodt.com/20210310", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001567892-21-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001567892-21-000008-xbrl.zip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